Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases

European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The CO...

Full description

Saved in:
Bibliographic Details
Main Author: Giuseppe Di Giovanni (auth)
Other Authors: Rona R. Ramsay (auth)
Format: Electronic Book Chapter
Language:English
Published: Frontiers Media SA 2017
Series:Frontiers Research Topics
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_60157
005 20210212
003 oapen
006 m o d
007 cr|mn|---annan
008 20210212s2017 xx |||||o ||| 0|eng d
020 |a 978-2-88945-123-4 
020 |a 9782889451234 
040 |a oapen  |c oapen 
024 7 |a 10.3389/978-2-88945-123-4  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a PSAN  |2 bicssc 
100 1 |a Giuseppe Di Giovanni  |4 auth 
700 1 |a Rona R. Ramsay  |4 auth 
245 1 0 |a Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases 
260 |b Frontiers Media SA  |c 2017 
300 |a 1 electronic resource (204 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Frontiers Research Topics 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The COST Action CM1103 "Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain" is a good example of the advances possible through interdisciplinary collaboration on difficult problems. COST Action CM1103 brought together 28 research groups from 18 countries to collaborate for four years on multi-target drug design for complex neuropathologies. The interdisciplinary expertise of the members is spans the range from computational enzymology to human studies, providing outstanding opportunities for the interdisciplinary development of trainees, and is reflected in the articles in this e-book. This Research Topic covers progress in multi-target drug design for the complex neuropathologies of the monoamine system that are apparent, for example, in Alzheimer's disease. After a mini-review to introduce the topic of multi-target drug design, the other articles review the Research topic from their own perspective, two from computational approaches, three from medicinal chemistry, two from molecular pharmacology, and two from studies in whole brain. This multi-faceted approach describes new compounds, new methodology, and advances in the basic science of understanding the brain. This Ebook is based upon work from COST Action (CM1103 "Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain"), supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a pan-European intergovernmental framework. Its mission is to enable break-through scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe's research and innovation capacities. It allows researchers, engineers and scholars to jointly develop their own ideas and take new initiatives across all fields of science and technology, while promoting multi- and interdisciplinary approaches. COST aims at fostering a better integration of less research intensive countries to the knowledge hubs of the European Research Area. The COST Association, an International not-for-profit Association under Belgian Law, integrates all management, governing and administrative functions necessary for the operation of the framework. The COST Association has currently 36 Member Countries. www.cost.eu 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Neurosciences  |2 bicssc 
653 |a Rationale drug design 
653 |a GPCR agonists 
653 |a Molecular dynamic simulations 
653 |a Neurodegenerative Diseases 
653 |a monoamine pharmacology 
653 |a Oxidative Stress 
653 |a Multi-target designed ligands 
653 |a Epilepsy 
653 |a Chemi-informatics 
856 4 0 |a www.oapen.org  |u http://journal.frontiersin.org/researchtopic/4246/structure-based-drug-design-for-diagnosis-and-treatment-of-neurological-diseases  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/60157  |7 0  |z DOAB: description of the publication